VERTEX Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VERTEX
VERTEX has ten approved drugs.
There are seventy-seven US patents protecting VERTEX drugs.
There are eight hundred and fifty-nine patent family members on VERTEX drugs in fifty-three countries and ninety-eight supplementary protection certificates in twenty countries.
Summary for VERTEX
| International Patents: | 859 |
| US Patents: | 77 |
| Tradenames: | 7 |
| Ingredients: | 7 |
| NDAs: | 10 |
| Patent Litigation for VERTEX: | See patent lawsuits for VERTEX |
| PTAB Cases with VERTEX as patent owner: | See PTAB cases with VERTEX as patent owner |
Drugs and US Patents for VERTEX
Expired US Patents for VERTEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-001 | Mar 17, 2015 | 8,629,162 | ⤷ Start Trial |
| Vertex Pharms Inc | SYMDEKO (COPACKAGED) | ivacaftor; ivacaftor, tezacaftor | TABLET;ORAL | 210491-001 | Feb 12, 2018 | 8,629,162 | ⤷ Start Trial |
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-001 | Oct 21, 2019 | 8,629,162 | ⤷ Start Trial |
| Vertex Pharms | KALYDECO | ivacaftor | TABLET;ORAL | 203188-001 | Jan 31, 2012 | 8,629,162 | ⤷ Start Trial |
| Vertex Pharms | INCIVEK | telaprevir | TABLET;ORAL | 201917-001 | May 23, 2011 | 7,820,671 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Premature patent expirations for VERTEX
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| ⤷ Start Trial | ⤷ Start Trial |
International Patents for VERTEX Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 567892 | ⤷ Start Trial |
| Taiwan | 200630093 | ⤷ Start Trial |
| Japan | 5734369 | ⤷ Start Trial |
| China | 101891680 | ⤷ Start Trial |
| Israel | 234307 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VERTEX Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1773816 | 15C0045 | France | ⤷ Start Trial | PRODUCT NAME: IVACAFTOR, OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120725 |
| 1320540 | PA2012003 | Lithuania | ⤷ Start Trial | PRODUCT NAME: TELAPREVIRUM; REGISTRATION NO/DATE: EU/1/11/720/001 20110919 |
| 2826776 | 2190015-4 | Sweden | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2- METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/18/1306, 2018-11-06; DEN 19 JUNI 2025 MEDDELADE PRV BESLUT OM RAETTAD SKYDDSTID FOER FOELJANDE TILLAEGGSSKYDD. 1790034-1 1490061-7 1790019-2 2090047-8 2390009-5 2390012-9 2090033-8 1790016-8 2190015-4 1990020-8 1090038-9 1190029-7 |
| 1773816 | 35/2015 | Austria | ⤷ Start Trial | PRODUCT NAME: N-(5-HYDROXY-2,4DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLIN-3-CARBOXAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/782/001, EU/1/12/782/002 (MITTEILUNG) 20120725 |
| 3752510 | LUC50026 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: VANZACAFTOR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY A CALCIUM SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/25/1943 20250701 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
